Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 + Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer
NCT06542549Phase 3Recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Mar 2025
- Primary completion
- Oct 2027
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised trial of cadonilimab in ovarian cancer (2 arms), sponsored by The First Affiliated Hospital of USTC. Primary endpoint: R0 Resection Rate at 6 months. Started Mar 2025; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT06542549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06542549.